Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) genotype 1 infection is a significant global health concern.
• Previous studies indicated high efficacy of sofosbuvir and ledipasvir combination therapy in treating HCV.
• Understanding optimal treatment durations and regimens for previously untreated patients is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of a fixed-dose combination of ledipasvir and sofosbuvir in previously untreated patients with chronic HCV genotype 1 infection.
• To compare treatment outcomes for 12-week versus 24-week regimens, with or without ribavirin.

Main Methods:

• A phase 3, open-label, randomized study enrolled 865 previously untreated patients with HCV genotype 1.
• Patients received once-daily ledipasvir-sofosbuvir for 12 or 24 weeks, with or without ribavirin.
• The primary endpoint was sustained virologic response (SVR) at 12 weeks post-therapy.

Main Results:

• Sustained virologic response rates were high across all arms: 99% for 12-week ledipasvir-sofosbuvir, 97% for 12-week ledipasvir-sofosbuvir plus ribavirin, 98% for 24-week ledipasvir-sofosbuvir, and 99% for 24-week ledipasvir-sofosbuvir plus ribavirin.
• No patients discontinued the 12-week ledipasvir-sofosbuvir regimen due to adverse events.
• Common adverse events included fatigue, headache, insomnia, and nausea.

Conclusions:

• Once-daily ledipasvir-sofosbuvir, with or without ribavirin for 12 or 24 weeks, demonstrates high efficacy in treating previously untreated patients with HCV genotype 1.
• Shortened treatment durations of 12 weeks are effective and well-tolerated.
• This regimen offers a promising option for HCV management.